Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) EBIT: 2022-2025

Historic EBIT for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to -$52.6 million.

  • Abivax's EBIT fell 38.35% to -$52.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$140.3 million, marking a year-over-year decrease of 62.09%. This contributed to the annual value of -$184.8 million for FY2024, which is 34.88% down from last year.
  • As of Q2 2025, Abivax's EBIT stood at -$52.6 million, which was down 6.01% from -$49.6 million recorded in Q1 2025.
  • In the past 5 years, Abivax's EBIT registered a high of -$66.11 during Q4 2022, and its lowest value of -$52.6 million during Q2 2025.
  • For the 3-year period, Abivax's EBIT averaged around -$31.5 million, with its median value being -$43.3 million (2024).
  • Data for Abivax's EBIT shows a maximum YoY tumbled of 107.34% (in 2023) over the last 5 years.
  • Over the past 4 years, Abivax's EBIT (Quarterly) stood at -$66.11 in 2022, then crashed by 107.34% to -$137.07 in 2023, then tumbled by 34.79% to -$184.76 in 2024, then tumbled by 38.35% to -$52.6 million in 2025.
  • Its last three reported values are -$52.6 million in Q2 2025, -$49.6 million for Q1 2025, and -$184.76 during Q4 2024.